{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:01:39Z","timestamp":1783033299054,"version":"3.54.6"},"reference-count":177,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sarcoidosis is an enigmatic, multisystem inflammatory disorder characterized by the formation of non-necrotizing granulomas in affected organs. Sarcoidosis may be self-limited or spontaneously resolve in up to two-thirds of individuals, but 10% to 30% develop a more chronic syndrome requiring long-term treatment. Most individuals will require treatment at some point during the course of the disease. Currently, guidelines recommend treatment in those at risk of future morbidity or organ dysfunction to preserve the quality of life. Careful identification of those likely to benefit from treatment is critical, as current agents are cumbersome to monitor and all have adverse effects. There is a lack of validated prognostic markers to identify those at risk for poor outcomes, but identifying characteristic manifestations of severe disease early can assist with treatment planning. While corticosteroids have been central to the treatment of sarcoidosis, newer data have challenged the current treatment paradigm of steroids as first-line agents. Recent and ongoing clinical trials may provide evidence for individualized approaches centered on shared decision-making with patients, as balancing the benefits of treatment must always be weighed with the potential for toxicity. This paper will provide an update on current treatment paradigms, new therapeutic strategies, and potential novel agents on the horizon while highlighting the existing challenges and barriers to progress.<\/jats:p>","DOI":"10.1055\/a-2746-4508","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T23:49:59Z","timestamp":1763164199000},"page":"582-593","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Sarcoidosis Over the Next Decade"],"prefix":"10.1055","volume":"46","author":[{"given":"Ashley","family":"Cattran","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"02","key":"ref1","first-page":"736","article-title":"Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","author":"ATS Journals","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"E D Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"R P Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref4","first-page":"119","article-title":"The clinical course of sarcoidosis: Presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"M A Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"106564","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study","volume":"187","author":"Y Zhou","year":"2021","journal-title":"Respir Med"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MCP.0000000000000080","article-title":"Morbidity and mortality in sarcoidosis","volume":"20","author":"A K Gerke","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/MCP.0000000000000077","article-title":"Clinical phenotypes in sarcoidosis","volume":"20","author":"C A Pereira","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/cells10040766","article-title":"Sarcoidosis: A clinical overview from symptoms to diagnosis","volume":"10","author":"P S\u00e8ve","year":"2021","journal-title":"Cells"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: Comparison of survival with the general population and causes of death","volume":"38","author":"A Nardi","year":"2011","journal-title":"Eur Respir J"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.trsl.2012.03.005","article-title":"The clinical and immunologic features of pulmonary fibrosis in sarcoidosis","volume":"160","author":"K C Patterson","year":"2012","journal-title":"Transl Res"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.chest.2021.07.2166","article-title":"National temporal trends in hospitalization and inpatient mortality in patients with pulmonary sarcoidosis in the United States between 2007 and 2018","volume":"161","author":"S Alqalyoobi","year":"2022","journal-title":"Chest"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1183\/09031936.00075307","article-title":"Epidemiology of sarcoidosis in Japan","volume":"31","author":"T Morimoto","year":"2008","journal-title":"Eur Respir J"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"J J Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2022.11.020","article-title":"Systemic treatment in sarcoidosis: Experience over two decades","volume":"108","author":"R Fern\u00e1ndez-Ram\u00f3n","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2040622318790197","article-title":"Epidemiology of sarcoidosis: Current findings and future directions","volume":"9","author":"E V Arkema","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1183\/13993003.00477-2016","article-title":"Sarcoidosis incidence and prevalence: A nationwide register-based assessment in Sweden","volume":"48","author":"E V Arkema","year":"2016","journal-title":"Eur Respir J"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"R P Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1378\/chest.14-1120","article-title":"Racial difference in sarcoidosis mortality in the United States","volume":"147","author":"M Mirsaeidi","year":"2015","journal-title":"Chest"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","article-title":"Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization","volume":"145","author":"B A Rybicki","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1183\/09031936.04.00070503","article-title":"Sarcoidosis: Social predictors of severity at presentation","volume":"24","author":"D L Rabin","year":"2004","journal-title":"Eur Respir J"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"R P Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"04","key":"ref22","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Wells Law","volume":"34","author":"R P Baughman","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.20696.1","article-title":"Developing better drugs for pulmonary sarcoidosis: Determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns","volume":"8","author":"M A Judson","year":"2019","journal-title":"F1000 Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"103179","DOI":"10.1016\/j.jaut.2024.103179","article-title":"Developmental drugs for sarcoidosis","volume":"149","author":"O N Obi","year":"2024","journal-title":"J Autoimmun"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccm.2015.08.014","article-title":"Quality of life assessment in sarcoidosis","volume":"36","author":"M A Judson","year":"2015","journal-title":"Clin Chest Med"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1164\/rccm.200705-742OC","article-title":"Phenotyping sarcoidosis from a pulmonary perspective","volume":"177","author":"A Prasse","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"R P Baughman","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"F Jeny","year":"2020","journal-title":"Respir Med"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"G Kirkil","year":"2018","journal-title":"Chest"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"1602396","DOI":"10.1183\/13993003.02396-2016","article-title":"Chronic pulmonary aspergillosis complicating sarcoidosis","volume":"49","author":"Y Uzunhan","year":"2017","journal-title":"Eur Respir J"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: A case-cohort study","volume":"2","author":"S L Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/MCP.0000000000001204","article-title":"Evolving management of sarcoidosis in the real world","volume":"31","author":"D A Culver","year":"2025","journal-title":"Curr Opin Pulm Med"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccm.2023.08.009","article-title":"Health-related quality of life assessment in sarcoidosis","volume":"45","author":"M A Judson","year":"2024","journal-title":"Clin Chest Med"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/diagnostics11061089","article-title":"Health-related quality of life (HRQoL) in sarcoidosis: Diagnosis, management, and health outcomes","volume":"11","author":"L A Saketkoo","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"00141","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: Patient treatment priorities","volume":"4","author":"R P Baughman","year":"2018","journal-title":"ERJ Open Res"},{"issue":"155","key":"ref36","doi-asserted-by":"crossref","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"F F Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.chest.2024.10.040","article-title":"Sarcoidosis treatment patterns in the United States: 2016-2022","volume":"167","author":"R Sangani","year":"2025","journal-title":"Chest"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"V Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/arrd.1973.107.4.609","article-title":"A controlled trial of prednisone treatment of sarcoidosis","volume":"107","author":"H L Israel","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"ref40","first-page":"526","article-title":"Treatment of sarcoidosis. Report of a controlled therapeutic trial","volume":"2","author":"D G James","year":"1967","journal-title":"Lancet"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1378\/chest.116.2.424","article-title":"Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: A double-blind, placebo-controlled multicenter study","volume":"116","author":"A Pietinalho","year":"1999","journal-title":"Chest"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1378\/chest.121.1.24","article-title":"Early treatment of stage II sarcoidosis improves 5-year pulmonary function","volume":"121","author":"A Pietinalho","year":"2002","journal-title":"Chest"},{"issue":"09","key":"ref43","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study","volume":"87","author":"M H Zaki","year":"1987","journal-title":"N Y State J Med"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: Effects of long term corticosteroid treatment","volume":"51","author":"G J Gibson","year":"1996","journal-title":"Thorax"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis","volume":"99","author":"R P Baughman","year":"2006","journal-title":"QJM"},{"issue":"03","key":"ref46","first-page":"623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"J E Gottlieb","year":"1997","journal-title":"Chest"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1164\/ajrccm.149.4.8143052","article-title":"Outcome of the treatment for sarcoidosis","volume":"149","author":"G W Hunninghake","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref48","first-page":"52","article-title":"The late follow-up of chronic sarcoid patients previously treated with corticosteroids","volume":"15","author":"G Rizzato","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"N A Khan","year":"2017","journal-title":"Respir Med"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: A systematic literature review","volume":"39","author":"J B Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: The results of a propensity analysis","volume":"109","author":"M A Judson","year":"2015","journal-title":"Respir Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.rmed.2017.10.022","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis","volume":"138S","author":"C E Broos","year":"2018","journal-title":"Respir Med"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"2300198","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40\u2009mg) versus low-dose (20\u2009mg) prednisolone for treating sarcoidosis: A randomised trial (SARCORT trial)","volume":"62","author":"S Dhooria","year":"2023","journal-title":"Eur Respir J"},{"issue":"01","key":"ref54","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial","volume":"17","author":"R P Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref55","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study","volume":"36","author":"C Fang","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"E E Lower","year":"1995","journal-title":"Arch Intern Med"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"A DM Vorselaars","year":"2013","journal-title":"Chest"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/resp.14001","article-title":"Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective \u2018target trial\u2019 emulated with Swedish real-world data","volume":"26","author":"M Rossides","year":"2021","journal-title":"Respirology"},{"issue":"01","key":"ref59","first-page":"87","article-title":"Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis","volume":"16","author":"S J Lewis","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","article-title":"Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen","volume":"14","author":"J M\u00fcller-Quernheim","year":"1999","journal-title":"Eur Respir J"},{"issue":"02","key":"ref61","first-page":"107","article-title":"Azathioprine treatment of chronic pulmonary sarcoidosis","volume":"2","author":"Y Pacheco","year":"1985","journal-title":"Sarcoidosis"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000345596","article-title":"Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study","volume":"86","author":"A K Brill","year":"2013","journal-title":"Respiration"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"101840","DOI":"10.1016\/j.pupt.2019.101840","article-title":"Mycophenolate mofetil as an alternative treatment in sarcoidosis","volume":"58","author":"S Papiris","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"issue":"13","key":"ref64","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.0b013e318212aafb","article-title":"Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy","volume":"76","author":"G Androdias","year":"2011","journal-title":"Neurology"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09273940902862992","article-title":"Mycophenolate mofetil therapy for sarcoidosis-associated uveitis","volume":"17","author":"P Bhat","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2133.2003.05042.x","article-title":"Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis","volume":"148","author":"D J Kouba","year":"2003","journal-title":"Br J Dermatol"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cardfail.2021.06.010","article-title":"Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent","volume":"27","author":"J M Griffin","year":"2021","journal-title":"J Card Fail"},{"issue":"24","key":"ref68","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"S Bitoun","year":"2016","journal-title":"Neurology"},{"issue":"01","key":"ref69","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"R P Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"05","key":"ref70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"D H Sahoo","year":"2011","journal-title":"Eur Respir J"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT)","volume":"220","author":"D Birnie","year":"2020","journal-title":"Am Heart J"},{"issue":"10","key":"ref72","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s10038-007-0185-7","article-title":"Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: A meta-analysis","volume":"52","author":"I Medica","year":"2007","journal-title":"J Hum Genet"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1164\/ajrccm\/145.1.187","article-title":"Lung-restricted activation of the alveolar macrophage\/monocyte system in pulmonary sarcoidosis","volume":"145","author":"J M\u00fcller-Quernheim","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/09629350120102325","article-title":"Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-alpha and INF-gamma","volume":"10","author":"M Sasaki","year":"2001","journal-title":"Mediators Inflamm"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.152.3.7663784","article-title":"Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis","volume":"152","author":"L Zheng","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref76","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/ajrccm.156.5.97-02050","article-title":"Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers","volume":"156","author":"M W Ziegenhagen","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"D R Roach","year":"2002","journal-title":"J Immunol"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"e0194430","DOI":"10.1371\/journal.pone.0194430","article-title":"TNF-\u03b1 blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines","volume":"13","author":"D AAD Silva","year":"2018","journal-title":"PLoS One"},{"issue":"07","key":"ref79","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"R P Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref80","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"M D Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"H A Crommelin","year":"2016","journal-title":"Respir Med"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis","volume":"83","author":"K E Hostettler","year":"2012","journal-title":"Respiration"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial","volume":"31","author":"M A Judson","year":"2008","journal-title":"Eur Respir J"},{"issue":"10","key":"ref84","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/ajrccm.184.10.1214","article-title":"Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis","volume":"184","author":"L S Kamphuis","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2022.12.003","article-title":"Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis","volume":"109","author":"M Rezaee","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"01","key":"ref86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"A Sakkat","year":"2022","journal-title":"Respir Res"},{"issue":"01","key":"ref87","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"N J Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"A D Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"issue":"02","key":"ref89","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"A D Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"C E Broos","year":"2013","journal-title":"Front Immunol"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccm.2008.03.014","article-title":"The immunology of sarcoidosis","volume":"29","author":"A K Gerke","year":"2008","journal-title":"Clin Chest Med"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jama.2011.10","article-title":"Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics","volume":"305","author":"M C Iannuzzi","year":"2011","journal-title":"JAMA"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"J Miedema","year":"2024","journal-title":"J Autoimmun"},{"issue":"S 06","key":"ref94","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis","volume":"14","author":"D R Moller","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"M A Judson","year":"2014","journal-title":"Eur Respir J"},{"issue":"26","key":"ref96","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"W Damsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref97","first-page":"187","article-title":"The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: A review of the literature","volume":"93","author":"A Wang","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"01","key":"ref98","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"T Zhou","year":"2017","journal-title":"Sci Rep"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"M A Friedman","year":"2021","journal-title":"Lung"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"W Damsky","year":"2022","journal-title":"Nat Commun"},{"issue":"02","key":"ref101","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series","volume":"84","author":"K L Kerkemeyer","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdcr.2021.08.012","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis","volume":"16","author":"R Talty","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"D A Culver","year":"2023","journal-title":"Chest"},{"issue":"01","key":"ref104","first-page":"e2023011","article-title":"Efzofitimod: A novel anti-inflammatory agent for sarcoidosis","volume":"40","author":"R P Baughman","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"03","key":"ref105","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1002\/iid3.575","article-title":"Neuropilin-2 regulates airway inflammation in a neutrophilic asthma model","volume":"10","author":"R M Immormino","year":"2022","journal-title":"Immun Inflamm Dis"},{"issue":"02","key":"ref106","doi-asserted-by":"crossref","first-page":"L202","DOI":"10.1152\/ajplung.00067.2018","article-title":"Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide","volume":"315","author":"R M Immormino","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system","volume":"90","author":"S Schellenburg","year":"2017","journal-title":"Mol Immunol"},{"issue":"S 65","key":"ref109","first-page":"OA3986","article-title":"Late Breaking Abstract - Immunomodulatory protein ATYR1923 disrupts an in vitro model of sarcoid granuloma formation","volume":"58","author":"S Paz","year":"2021","journal-title":"Eur Respir J"},{"key":"ref110","volume-title":"EFZO-FIT, the largest ever interventional trial in pulmonary sarcoidosis","author":"D Culver","year":"2025"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1066454","DOI":"10.3389\/fphar.2023.1066454","article-title":"Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment","volume":"14","author":"E Offman","year":"2023","journal-title":"Front Pharmacol"},{"issue":"01","key":"ref112","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"V Panwar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"ref113","doi-asserted-by":"crossref","first-page":"e030478","DOI":"10.1161\/JAHA.123.030478","article-title":"An mTORC1-dependent mouse model for cardiac sarcoidosis","volume":"12","author":"C Bueno-Beti","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref114","doi-asserted-by":"crossref","first-page":"2002695","DOI":"10.1183\/13993003.02695-2020","article-title":"Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis","volume":"57","author":"E D Crouser","year":"2021","journal-title":"Eur Respir J"},{"issue":"03","key":"ref115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"M Linke","year":"2017","journal-title":"Nat Immunol"},{"issue":"02","key":"ref116","doi-asserted-by":"crossref","first-page":"1900430","DOI":"10.1183\/13993003.00430-2019","article-title":"Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis","volume":"54","author":"A Calender","year":"2019","journal-title":"Eur Respir J"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"567342","DOI":"10.3389\/fimmu.2020.567342","article-title":"Single cell transcriptomics implicate novel monocyte and T cell immune dysregulation in sarcoidosis","volume":"11","author":"L Garman","year":"2020","journal-title":"Front Immunol"},{"issue":"09","key":"ref118","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1164\/rccm.202004-0914IM","article-title":"Successful response to treatment with sirolimus in pulmonary sarcoidosis","volume":"202","author":"N Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref119","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.pulmoe.2024.03.002","article-title":"Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis","volume":"30","author":"R Hindr\u00e9","year":"2024","journal-title":"Pulmonology"},{"issue":"08","key":"ref120","doi-asserted-by":"crossref","first-page":"e235372","DOI":"10.1136\/bcr-2020-235372","article-title":"Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus","volume":"13","author":"K J Kelleher","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"08","key":"ref121","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/j.1432-2277.2011.01256.x","article-title":"Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation","volume":"24","author":"T M Manzia","year":"2011","journal-title":"Transpl Int"},{"issue":"02","key":"ref122","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: A single-centre trial","volume":"6","author":"A Redl","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"07","key":"ref123","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.cardfail.2024.10.444","article-title":"Utility of mechanistic target of rapamycin inhibitors in cardiac sarcoidosis","volume":"31","author":"D Richards","year":"2025","journal-title":"J Card Fail"},{"issue":"05","key":"ref124","doi-asserted-by":"crossref","first-page":"e011869","DOI":"10.1161\/CIRCEP.123.011869","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: A pilot study","volume":"16","author":"J Kron","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"09","key":"ref125","doi-asserted-by":"crossref","first-page":"e007582","DOI":"10.1161\/CIRCEP.119.007582","article-title":"Inflammasome formation in granulomas in cardiac sarcoidosis","volume":"12","author":"J Kron","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"04","key":"ref126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000029536","article-title":"Significance of the interleukin-1 receptor antagonist\/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis","volume":"67","author":"T Mikuniya","year":"2000","journal-title":"Respiration"},{"issue":"03","key":"ref127","first-page":"629","article-title":"Direct evidence for granuloma-inducing activity of interleukin-1. Induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads","volume":"130","author":"K Kasahara","year":"1988","journal-title":"Am J Pathol"},{"issue":"12","key":"ref128","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: Environmental and occupational risk factors","volume":"170","author":"L S Newman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref129","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/thx.43.7.516","article-title":"Smoking and pulmonary sarcoidosis: Effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease","volume":"43","author":"D Valeyre","year":"1988","journal-title":"Thorax"},{"issue":"08","key":"ref130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.200210-1154OC","article-title":"Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro","volume":"169","author":"M R Blanchet","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref131","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1378\/chest.12-0383","article-title":"Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis","volume":"143","author":"M W Julian","year":"2013","journal-title":"Chest"},{"issue":"05","key":"ref132","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s10753-019-01027-9","article-title":"Alpha7 nicotinic acetylcholine receptor alleviates inflammatory bowel disease through induction of AMPK-mTOR-p70S6K-mediated autophagy","volume":"42","author":"B Z Shao","year":"2019","journal-title":"Inflammation"},{"issue":"03","key":"ref133","first-page":"971","article-title":"Activation of the \u03b17 nicotinic receptor promotes lipopolysaccharide-induced conversion of M1 microglia to M2","volume":"9","author":"Q Zhang","year":"2017","journal-title":"Am J Transl Res"},{"issue":"04","key":"ref134","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chest.2021.05.031","article-title":"A pilot randomized trial of transdermal nicotine for pulmonary sarcoidosis","volume":"160","author":"E D Crouser","year":"2021","journal-title":"Chest"},{"issue":"01","key":"ref135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s41030-022-00181-0","article-title":"repository corticotropin injection for the treatment of pulmonary sarcoidosis: A narrative review","volume":"8","author":"M Mirsaeidi","year":"2022","journal-title":"Pulm Ther"},{"issue":"05","key":"ref136","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/10799893.2020.1818094","article-title":"Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists","volume":"41","author":"Y J Huang","year":"2021","journal-title":"J Recept Signal Transduct Res"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2015.11.007","article-title":"A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients","volume":"110","author":"R P Baughman","year":"2016","journal-title":"Respir Med"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"1753466619888127","DOI":"10.1177\/1753466619888127","article-title":"Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: Retrospective analysis of medical records","volume":"13","author":"I Chopra","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"03","key":"ref139","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"R P Baughman","year":"2017","journal-title":"Lung"},{"issue":"02","key":"ref140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s41030-023-00222-2","article-title":"Results from a Phase 4, multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for the treatment of pulmonary sarcoidosis","volume":"9","author":"M Mirsaeidi","year":"2023","journal-title":"Pulm Ther"},{"issue":"05","key":"ref141","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"N J Sweiss","year":"2014","journal-title":"Eur Respir J"},{"issue":"08","key":"ref142","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00415-025-13209-7","article-title":"Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: A multi-center retrospective study","volume":"272","author":"S K Hutto","year":"2025","journal-title":"J Neurol"},{"issue":"02","key":"ref143","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: A single-center experience","volume":"28","author":"M Elwazir","year":"2022","journal-title":"J Card Fail"},{"issue":"11","key":"ref144","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"M Drent","year":"2021","journal-title":"N Engl J Med"},{"issue":"05","key":"ref145","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1148\/rg.2018180053","article-title":"PET\/CT in the diagnosis and workup of sarcoidosis: Focus on atypical manifestations","volume":"38","author":"G Akaike","year":"2018","journal-title":"Radiographics"},{"issue":"03","key":"ref146","first-page":"e2023027","article-title":"Pulmonary fibrosis in sarcoidosis","volume":"40","author":"H Asif","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"01","key":"ref147","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/jcm13010241","article-title":"Clinical manifestations and management of fibrotic pulmonary sarcoidosis","volume":"13","author":"J S Kim","year":"2023","journal-title":"J Clin Med"},{"issue":"03","key":"ref148","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"R L Mostard","year":"2013","journal-title":"Respir Med"},{"issue":"01","key":"ref149","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ccm.2023.08.011","article-title":"Fibrotic pulmonary sarcoidosis","volume":"45","author":"H Nunes","year":"2024","journal-title":"Clin Chest Med"},{"issue":"18","key":"ref150","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"K R Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref151","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"T M Maher","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"22","key":"ref153","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"T M Maher","year":"2025","journal-title":"N Engl J Med"},{"issue":"05","key":"ref154","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1378\/chest.09-2002","article-title":"Survival in sarcoidosis-associated pulmonary hypertension: The importance of hemodynamic evaluation","volume":"138","author":"R P Baughman","year":"2010","journal-title":"Chest"},{"issue":"04","key":"ref155","doi-asserted-by":"crossref","first-page":"1700465","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"A Boucly","year":"2017","journal-title":"Eur Respir J"},{"issue":"01","key":"ref156","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/thx.2005.042838","article-title":"Pulmonary hypertension associated with sarcoidosis: Mechanisms, haemodynamics and prognosis","volume":"61","author":"H Nunes","year":"2006","journal-title":"Thorax"},{"issue":"05","key":"ref157","doi-asserted-by":"crossref","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: Results from an international registry","volume":"55","author":"O A Shlobin","year":"2020","journal-title":"Eur Respir J"},{"issue":"04","key":"ref158","doi-asserted-by":"crossref","first-page":"1701725","DOI":"10.1183\/13993003.01725-2017","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: So close, and yet so far","volume":"50","author":"R P Baughman","year":"2017","journal-title":"Eur Respir J"},{"issue":"04","key":"ref159","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1183\/09031936.93.03040403","article-title":"Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis","volume":"3","author":"J Gluskowski","year":"1990","journal-title":"Eur Respir J"},{"issue":"06","key":"ref160","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1378\/chest.08-1881","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience","volume":"135","author":"C F Barnett","year":"2009","journal-title":"Chest"},{"issue":"02","key":"ref161","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"R P Baughman","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"04","key":"ref162","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.14-2546","article-title":"Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: A retrospective case series","volume":"148","author":"C A Bonham","year":"2015","journal-title":"Chest"},{"issue":"02","key":"ref163","first-page":"139","article-title":"Ambrisentan for sarcoidosis associated pulmonary hypertension","volume":"28","author":"M A Judson","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref164","doi-asserted-by":"crossref","first-page":"e12245","DOI":"10.1002\/pul2.12245","article-title":"Pulmonary vasodilator therapy in sarcoidosis-associated pulmonary hypertension may decrease lung function decline and mortality","volume":"13","author":"S Gayen","year":"2023","journal-title":"Pulm Circ"},{"issue":"04","key":"ref165","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: A double-blind placebo controlled randomized trial","volume":"145","author":"R P Baughman","year":"2014","journal-title":"Chest"},{"issue":"02","key":"ref166","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.chest.2021.07.2162","article-title":"Riociguat for sarcoidosis-associated pulmonary hypertension: Results of a 1-year double-blind, placebo-controlled trial","volume":"161","author":"R P Baughman","year":"2022","journal-title":"Chest"},{"issue":"04","key":"ref167","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"A Waxman","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref168","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/jcm9020390","article-title":"Comprehensive care for patients with sarcoidosis","volume":"9","author":"C C Moor","year":"2020","journal-title":"J Clin Med"},{"issue":"04","key":"ref169","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4187\/respcare.04312","article-title":"Effects of inspiratory muscle training in subjects with sarcoidosis: A randomized controlled clinical trial","volume":"61","author":"M N Karadall\u0131","year":"2016","journal-title":"Respir Care"},{"issue":"05","key":"ref170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"E E Lower","year":"2008","journal-title":"Chest"},{"issue":"02","key":"ref171","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: A double-blind, placebo-controlled, crossover trial","volume":"45","author":"E E Lower","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"01","key":"ref172","first-page":"53","article-title":"Does physical training reduce fatigue in sarcoidosis?","volume":"32","author":"R Marcellis","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"02","key":"ref173","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: A randomized controlled trial","volume":"38","author":"I Naz","year":"2018","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"05","key":"ref174","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00408-015-9784-9","article-title":"Benefits of physical training in sarcoidosis","volume":"193","author":"B Strookappe","year":"2015","journal-title":"Lung"},{"issue":"01","key":"ref175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2010.09.015","article-title":"Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis","volume":"105","author":"J G Parambil","year":"2011","journal-title":"Respir Med"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"J O Tavee","year":"2017","journal-title":"Respir Med"},{"issue":"21","key":"ref177","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.16680","article-title":"Racial and ethnic representation in US Clinical Trials of New Drugs and Biologics, 2015-2019","volume":"326","author":"M Lolic","year":"2021","journal-title":"JAMA"},{"issue":"02","key":"ref178","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"R P Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"04","key":"ref179","first-page":"215","article-title":"Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease","volume":"60","author":"O Selroos","year":"1979","journal-title":"Scand J Respir Dis"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2746-4508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T23:33:18Z","timestamp":1767655998000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2746-4508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":177,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2746-4508","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,14]]},"published":{"date-parts":[[2025,11,14]]}}}